Quoin Pharmaceuticals reports $50 million private placement in Form D filing
The Israel-incorporated pharmaceutical company sold securities to 33 investors with a first sale date of August 31, 2026, according to its SEC filing.
Quoin Pharmaceuticals Ltd. filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The filing marks a new notice with a date of first sale listed as August 31, 2026.1 The company, incorporated in Israel, previously operated under the names Cellect Biotechnology Ltd. and Cellect Biomed Ltd.1
The total offering amount and total amount sold were each listed as $50,000,649, with the total remaining to be sold at $0.1 The company clarified that the total offering amount reflects gross proceeds assuming cash exercise of all warrants issued in the private placement.1 The securities offered included equity, options, warrants or other rights to acquire another security, and securities to be acquired upon exercise of those rights.1
The filing states that 33 investors had already invested in the offering.1 Quoin claimed the Rule 506(b) exemption under Regulation D.1
Sales commissions totaled an estimated $3,000,039, consisting of fees due to placement agents equal in aggregate to 6.0% of gross offering proceeds assuming cash exercise of all warrants issued, with the lead placement agent also entitled to reimbursement for reasonable out-of-pocket expenses not included in that figure.1 The placement agents named in the filing were Leerink Partners LLC, BTIG, LLC, and Lake Street Capital Markets, LLC.1
The filing states that no offering proceeds are set aside for payments to named officers or directors.1
The notice was signed by Sally Lawlor, Chief Financial Officer of Quoin Pharmaceuticals Ltd., on September 10, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.